Lista Osiągnięć Pracowników Kliniki Onkologii i Immunoonkologii

1. Gąsowska-Bajger B, Gąsowska-Bodnar A, Knapp P, Bodnar L.
   Prognostic Significance of Survivin Expression in Patients with Ovarian Carcinoma: A Meta- Analysis.
   J Clin Med.
   2021 Feb 21;10(4):879.
   IF: 3.303
   MNiSW: 140
2. Cassetta L, Bruderek K, Skrzeczynska-Moncznik J, Osiecka O, Hu X, Rundgren IM, Lin A, Santegoets K, Horzum U, Godinho-Santos A, Zelinskyy G, Garcia-Tellez T, Bjelica S, Taciak B, Kittang AO, Höing B, Lang S, Dixon M, Müller V, Utikal JS, Karakoç D, Yilmaz KB, Górka E, Bodnar L, Anastasiou OE, Bourgeois C, Badura R, Kapinska-Mrowiecka M, Gotic M, Ter Laan M, Kers-Rebel E, Król M, Santibañez JF, Müller-Trutwin M, Dittmer U, de Sousa AE, Esendağlı G, Adema G, Loré K, Ersvær E, Umansky V, Pollard JW, Cichy J, Brandau S.
   Differential expansion of circulating human MDSC subsets in patients with cancer, infection and
   inflammation.
   J Immunother Cancer.
   2020 Sep;8(2):e001223.
   IF: 9.913
   MNiSW: 140
3. Sigorski D, Iżycka-Świeszewska E, Bodnar L.
   Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
   Target Oncol.
   2020 Dec;15(6):709-722.
   IF: 4.030
   MNiSW: 100
4. Klemba A, Bodnar L, Was H, Brodaczewska KK, Wcislo G, Szczylik CA, Kieda C.
   Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment:
   Significance for Chemo- and Immunotherapies.
   Int J Mol Sci.
   2020 Dec 14;21(24):9492.
   IF: 4.556
   MNiSW: 140
5. Sigorski D, Sobczuk P, Osmola M, Kuć K, Walerzak A, Wilk M, Ciszewski T, Kopeć S, Hryń K, Rutkowski P, Stec R, Szczylik C, Bodnar L.
   Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic
   therapy.
   ESMO Open.
   2020 Oct;5(5):e000970.
   IF: 5.329
   MNiSW: 20
6. Palomero Luis, Bodnar Lubomir, Mateo Francesca, Herranz-Ors Carmen, Espin Roderic, Garcia-Varelo Mar, Jesiotr Marzenna, Ruiz de Garibay Gorka, Casanovas Oriol, Lopez Jose I., Pujana Miquel Angel.
   EVI1 as a prognostic and predictive biomarker of clear cell renal cell carcinoma.
   Cancers
   2020 : Vol. 12, nr 2, s. 1-12, bibliogr. 48 poz., sum.
   IF: 6.162
   MNiSW: 140.000
7. Sejda A, Sigorski D, Gulczyński J, Wesołowski W, Kitlińska J, Iżycka- Świeszewska E.
   Complexity of Neural Component of Tumor Microenvironment in Prostate Cancer. Pathobiology.
   2020;87(2):87-99.
   IF: 1.985
   MNiSW: 70.000
8. Rogowski W, Wachuła E, Gorzelak A, Lebiedzińska A, Sulżyc-Bielicka V, Iżycka-
   Świeszewska E, Żołnierek J, Kos-Kudła B. Capecitabine and temozolomide
   combination for treatment of high-grade, well-differentiated neuroendocrine
   tumour and poorly-differentiated neuroendocrine carcinoma – retrospective
   analysis.
   Endokrynol Pol.
   2019;70(4):313-317.
   IF: 1.322
9. Izycka-Swieszewska E, Bien E, Stefanowicz J, Szurowska E, Szutowicz-Zielinska
   E, Koczkowska M, Sigorski D, Kloc W, Rogowski W, Adamkiewicz-Drozynska E.
   Malignant Gliomas as Second Neoplasms in Pediatric Cancer Survivors: Neuropathological Study.
   Biomed Res Int.
   2018 Apr 1;2018:4596812.
   IF: 2.276